 Elizabeth McFarland
Concepts (356)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 43 | 2023 | 2469 | 2.730 |
Why?
| | HIV-1 | 23 | 2023 | 768 | 2.700 |
Why?
| | Respiratory Syncytial Virus Vaccines | 6 | 2022 | 24 | 2.500 |
Why?
| | Respiratory Syncytial Virus Infections | 6 | 2022 | 97 | 2.320 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2022 | 60 | 2.260 |
Why?
| | Anti-Retroviral Agents | 12 | 2023 | 207 | 1.840 |
Why?
| | Infectious Disease Transmission, Vertical | 15 | 2023 | 152 | 1.780 |
Why?
| | Viral Proteins | 3 | 2020 | 281 | 1.710 |
Why?
| | HIV Antibodies | 10 | 2023 | 49 | 1.680 |
Why?
| | Antibodies, Viral | 7 | 2022 | 520 | 1.100 |
Why?
| | Antibodies, Neutralizing | 7 | 2022 | 221 | 0.990 |
Why?
| | Antibodies, Monoclonal | 5 | 2021 | 1262 | 0.810 |
Why?
| | Pregnancy Complications, Infectious | 7 | 2016 | 288 | 0.800 |
Why?
| | Gene Deletion | 2 | 2020 | 356 | 0.760 |
Why?
| | AIDS Vaccines | 7 | 2018 | 41 | 0.710 |
Why?
| | Atazanavir Sulfate | 2 | 2017 | 41 | 0.670 |
Why?
| | Breast Feeding | 3 | 2023 | 368 | 0.660 |
Why?
| | HIV Protease Inhibitors | 2 | 2017 | 64 | 0.650 |
Why?
| | Ritonavir | 2 | 2017 | 71 | 0.650 |
Why?
| | Anti-HIV Agents | 9 | 2023 | 666 | 0.640 |
Why?
| | Vaccines, Attenuated | 6 | 2022 | 112 | 0.610 |
Why?
| | Infant, Newborn | 20 | 2023 | 5043 | 0.570 |
Why?
| | Nelfinavir | 1 | 2016 | 8 | 0.530 |
Why?
| | Lyme Disease | 1 | 2016 | 32 | 0.530 |
Why?
| | Vaccination | 5 | 2020 | 1204 | 0.530 |
Why?
| | Syncope | 1 | 2016 | 37 | 0.520 |
Why?
| | Lopinavir | 1 | 2016 | 29 | 0.520 |
Why?
| | Patient Dropouts | 1 | 2016 | 66 | 0.520 |
Why?
| | Bradycardia | 1 | 2016 | 48 | 0.520 |
Why?
| | Infant | 28 | 2023 | 7959 | 0.520 |
Why?
| | Health Resources | 1 | 2016 | 122 | 0.480 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 104 | 0.470 |
Why?
| | HIV | 5 | 2014 | 208 | 0.440 |
Why?
| | Patient Compliance | 2 | 2018 | 524 | 0.430 |
Why?
| | HIV Envelope Protein gp120 | 5 | 2017 | 56 | 0.420 |
Why?
| | Immunogenicity, Vaccine | 4 | 2021 | 25 | 0.400 |
Why?
| | Child | 35 | 2023 | 18404 | 0.400 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 959 | 0.390 |
Why?
| | Virus Replication | 4 | 2020 | 395 | 0.390 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2005 | 154 | 0.380 |
Why?
| | Humans | 65 | 2023 | 114623 | 0.360 |
Why?
| | Female | 42 | 2023 | 59466 | 0.340 |
Why?
| | Male | 34 | 2021 | 55554 | 0.300 |
Why?
| | Viral Load | 9 | 2017 | 405 | 0.300 |
Why?
| | Adolescent | 25 | 2023 | 17831 | 0.300 |
Why?
| | HIV Seropositivity | 2 | 2023 | 109 | 0.290 |
Why?
| | Double-Blind Method | 3 | 2020 | 1660 | 0.290 |
Why?
| | RNA, Viral | 8 | 2023 | 565 | 0.280 |
Why?
| | Antibodies, Bacterial | 2 | 2018 | 119 | 0.260 |
Why?
| | Dyslipidemias | 2 | 2017 | 154 | 0.250 |
Why?
| | Antiretroviral Therapy, Highly Active | 6 | 2017 | 256 | 0.250 |
Why?
| | Immunoglobulin G | 3 | 2022 | 770 | 0.240 |
Why?
| | Young Adult | 12 | 2021 | 10455 | 0.240 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 192 | 0.240 |
Why?
| | Viremia | 3 | 2011 | 122 | 0.230 |
Why?
| | Gene Products, gag | 2 | 1994 | 36 | 0.220 |
Why?
| | Child, Preschool | 20 | 2022 | 9108 | 0.220 |
Why?
| | Pregnancy | 10 | 2023 | 5517 | 0.210 |
Why?
| | Drug Resistance, Viral | 2 | 2016 | 99 | 0.200 |
Why?
| | CD4 Lymphocyte Count | 4 | 2017 | 257 | 0.200 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2021 | 33 | 0.190 |
Why?
| | Half-Life | 1 | 2021 | 141 | 0.190 |
Why?
| | T-Lymphocytes | 2 | 2009 | 1736 | 0.190 |
Why?
| | Mitochondrial Diseases | 1 | 2021 | 77 | 0.190 |
Why?
| | Immunization Schedule | 2 | 2018 | 184 | 0.180 |
Why?
| | Drug Therapy, Combination | 4 | 2017 | 951 | 0.180 |
Why?
| | Lymphocyte Activation | 4 | 2017 | 1037 | 0.180 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 162 | 0.180 |
Why?
| | RNA, Small Untranslated | 1 | 2020 | 15 | 0.180 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 2 | 2017 | 16 | 0.170 |
Why?
| | Cytokines | 2 | 2021 | 1840 | 0.170 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 176 | 0.170 |
Why?
| | Body Temperature | 1 | 2020 | 208 | 0.160 |
Why?
| | Insulin Resistance | 3 | 2019 | 1072 | 0.160 |
Why?
| | Squalene | 2 | 2017 | 5 | 0.160 |
Why?
| | Point Mutation | 1 | 2020 | 216 | 0.160 |
Why?
| | Immunologic Memory | 2 | 2021 | 313 | 0.160 |
Why?
| | Haemophilus Vaccines | 2 | 2018 | 27 | 0.160 |
Why?
| | Immunocompromised Host | 2 | 2000 | 195 | 0.160 |
Why?
| | Metabolic Syndrome | 1 | 2021 | 321 | 0.150 |
Why?
| | Interleukin-12 | 1 | 1998 | 110 | 0.150 |
Why?
| | Darunavir | 1 | 2017 | 17 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 333 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1842 | 0.140 |
Why?
| | Immunoglobulin A | 2 | 2017 | 166 | 0.140 |
Why?
| | Therapeutic Equipoise | 1 | 2017 | 2 | 0.140 |
Why?
| | Interferon-gamma | 5 | 2012 | 719 | 0.140 |
Why?
| | Antibody Formation | 1 | 2018 | 266 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 123 | 0.140 |
Why?
| | Uganda | 1 | 2017 | 70 | 0.140 |
Why?
| | Lymphopoiesis | 1 | 2017 | 24 | 0.140 |
Why?
| | Receptors, CCR5 | 1 | 2017 | 54 | 0.140 |
Why?
| | CD4-CD8 Ratio | 1 | 2016 | 19 | 0.140 |
Why?
| | Adult | 15 | 2023 | 30528 | 0.140 |
Why?
| | Mothers | 3 | 2017 | 651 | 0.140 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 1 | 2016 | 17 | 0.140 |
Why?
| | Adoption | 1 | 2016 | 38 | 0.130 |
Why?
| | Virus Latency | 1 | 2016 | 80 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 253 | 0.130 |
Why?
| | Early Diagnosis | 1 | 2016 | 217 | 0.120 |
Why?
| | Chickenpox Vaccine | 1 | 2015 | 69 | 0.120 |
Why?
| | Body Height | 2 | 2017 | 180 | 0.120 |
Why?
| | Disease Susceptibility | 1 | 2017 | 316 | 0.120 |
Why?
| | Gene Products, env | 1 | 1994 | 7 | 0.120 |
Why?
| | Haemophilus influenzae type b | 1 | 2014 | 10 | 0.120 |
Why?
| | Developing Countries | 1 | 2016 | 235 | 0.120 |
Why?
| | Bacterial Capsules | 1 | 2014 | 28 | 0.120 |
Why?
| | Antibody Affinity | 1 | 2014 | 52 | 0.120 |
Why?
| | Chickenpox | 1 | 2015 | 93 | 0.120 |
Why?
| | Retrospective Studies | 8 | 2023 | 12542 | 0.120 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2000 | 217 | 0.120 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.120 |
Why?
| | Lipids | 1 | 2017 | 580 | 0.110 |
Why?
| | Intestines | 1 | 2017 | 326 | 0.110 |
Why?
| | Puberty, Delayed | 1 | 2013 | 5 | 0.110 |
Why?
| | Mitochondria | 2 | 2021 | 747 | 0.110 |
Why?
| | Vaccines | 1 | 2018 | 375 | 0.110 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1993 | 34 | 0.110 |
Why?
| | Patient Selection | 1 | 2017 | 641 | 0.110 |
Why?
| | Mycobacterium chelonae | 1 | 1993 | 8 | 0.110 |
Why?
| | Cohort Studies | 7 | 2021 | 4894 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2016 | 1727 | 0.110 |
Why?
| | Child Development | 1 | 2017 | 385 | 0.100 |
Why?
| | Pediatric Obesity | 1 | 2019 | 488 | 0.100 |
Why?
| | Bone Density | 1 | 2016 | 432 | 0.100 |
Why?
| | Cell Movement | 1 | 2017 | 868 | 0.100 |
Why?
| | Prospective Studies | 4 | 2017 | 6217 | 0.100 |
Why?
| | Lamivudine | 3 | 2023 | 59 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 931 | 0.100 |
Why?
| | United States | 9 | 2023 | 12176 | 0.100 |
Why?
| | Body Weight | 2 | 2017 | 868 | 0.100 |
Why?
| | STAT1 Transcription Factor | 1 | 2012 | 64 | 0.100 |
Why?
| | Body Fat Distribution | 1 | 2011 | 46 | 0.100 |
Why?
| | Epitopes | 2 | 2022 | 435 | 0.090 |
Why?
| | Mycobacterium avium Complex | 1 | 2012 | 92 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 928 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 585 | 0.090 |
Why?
| | Exercise | 1 | 2021 | 1644 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 452 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 319 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2003 | 413 | 0.090 |
Why?
| | Biomarkers | 4 | 2021 | 3408 | 0.080 |
Why?
| | Algorithms | 1 | 2016 | 1466 | 0.080 |
Why?
| | Phenotype | 1 | 2017 | 2796 | 0.080 |
Why?
| | Freezing | 1 | 2009 | 84 | 0.080 |
Why?
| | Blood | 1 | 2009 | 96 | 0.080 |
Why?
| | Staff Development | 1 | 2009 | 39 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 2894 | 0.080 |
Why?
| | Specimen Handling | 1 | 2009 | 155 | 0.080 |
Why?
| | Adipose Tissue | 1 | 2011 | 539 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2009 | 79 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 797 | 0.070 |
Why?
| | Faculty | 1 | 2009 | 130 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 68 | 0.070 |
Why?
| | Enterovirus A, Human | 1 | 2007 | 12 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 3 | 2013 | 493 | 0.070 |
Why?
| | Vaccines, Synthetic | 3 | 2005 | 124 | 0.070 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2007 | 63 | 0.070 |
Why?
| | Polymerase Chain Reaction | 4 | 2011 | 993 | 0.070 |
Why?
| | Academic Medical Centers | 1 | 2009 | 410 | 0.070 |
Why?
| | DNA, Viral | 2 | 2000 | 350 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1998 | 195 | 0.060 |
Why?
| | Colorado | 3 | 2023 | 4099 | 0.060 |
Why?
| | Enterovirus Infections | 1 | 2007 | 160 | 0.060 |
Why?
| | Cell Line | 3 | 2012 | 2635 | 0.060 |
Why?
| | C-Reactive Protein | 2 | 2021 | 362 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4411 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2007 | 307 | 0.060 |
Why?
| | Isoantigens | 1 | 1984 | 17 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2006 | 248 | 0.060 |
Why?
| | Linear Models | 2 | 2020 | 768 | 0.060 |
Why?
| | Comorbidity | 2 | 2021 | 1448 | 0.060 |
Why?
| | Risk Factors | 4 | 2021 | 8628 | 0.060 |
Why?
| | Thymus Gland | 1 | 1984 | 296 | 0.050 |
Why?
| | Cote d'Ivoire | 1 | 2023 | 8 | 0.050 |
Why?
| | Tablets | 1 | 2023 | 36 | 0.050 |
Why?
| | Immunophenotyping | 2 | 1994 | 274 | 0.050 |
Why?
| | Regression Analysis | 2 | 2021 | 944 | 0.050 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2022 | 46 | 0.050 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.050 |
Why?
| | Cough | 1 | 2022 | 107 | 0.050 |
Why?
| | Emtricitabine | 1 | 2023 | 147 | 0.050 |
Why?
| | Pyridones | 1 | 2023 | 123 | 0.050 |
Why?
| | Polysorbates | 2 | 2017 | 35 | 0.050 |
Why?
| | Lung | 1 | 2014 | 3558 | 0.050 |
Why?
| | Tenofovir | 1 | 2023 | 204 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 4405 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 45 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 61 | 0.050 |
Why?
| | Ganciclovir | 1 | 2000 | 49 | 0.050 |
Why?
| | Sex Factors | 2 | 2019 | 1715 | 0.050 |
Why?
| | Computer Simulation | 1 | 2005 | 872 | 0.050 |
Why?
| | Adjuvants, Immunologic | 2 | 2017 | 206 | 0.040 |
Why?
| | Africa | 1 | 2020 | 94 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 134 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2021 | 87 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2023 | 544 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 119 | 0.040 |
Why?
| | Prevalence | 2 | 2016 | 2249 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3003 | 0.040 |
Why?
| | HIV Seronegativity | 1 | 2019 | 24 | 0.040 |
Why?
| | HLA-D Antigens | 1 | 1999 | 34 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2387 | 0.040 |
Why?
| | Risk | 1 | 2021 | 812 | 0.040 |
Why?
| | Mutation | 3 | 2018 | 3344 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 581 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2019 | 183 | 0.040 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1998 | 41 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 25 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1998 | 43 | 0.040 |
Why?
| | Vaccines, Combined | 1 | 2018 | 46 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2000 | 180 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2018 | 22 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 953 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 2018 | 46 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2019 | 224 | 0.040 |
Why?
| | Drug Resistance, Microbial | 2 | 2000 | 66 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2019 | 307 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2005 | 2762 | 0.040 |
Why?
| | Case Management | 1 | 2018 | 62 | 0.040 |
Why?
| | Cholesterol | 1 | 2019 | 367 | 0.040 |
Why?
| | Antigens, Viral | 1 | 1998 | 176 | 0.040 |
Why?
| | Immune Tolerance | 1 | 1999 | 323 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1998 | 170 | 0.040 |
Why?
| | Triglycerides | 1 | 2019 | 467 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.040 |
Why?
| | Treatment Adherence and Compliance | 1 | 2017 | 18 | 0.030 |
Why?
| | Lymphocyte Count | 2 | 2009 | 133 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 95 | 0.030 |
Why?
| | Cell Division | 1 | 1998 | 758 | 0.030 |
Why?
| | Treatment Failure | 1 | 2017 | 331 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 383 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 248 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1214 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2017 | 147 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2021 | 9084 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2017 | 138 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 16 | 0.030 |
Why?
| | Malnutrition | 1 | 2016 | 62 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2015 | 138 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2018 | 138 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2000 | 645 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 122 | 0.030 |
Why?
| | Counseling | 1 | 2018 | 342 | 0.030 |
Why?
| | Genes, pol | 1 | 1994 | 7 | 0.030 |
Why?
| | Coinfection | 1 | 2016 | 120 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 287 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 125 | 0.030 |
Why?
| | Vaccines, Conjugate | 1 | 2014 | 59 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2008 | 3881 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 143 | 0.030 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 151 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2537 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2013 | 53 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2013 | 33 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 177 | 0.030 |
Why?
| | Tuberculosis, Cutaneous | 1 | 1993 | 3 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 150 | 0.030 |
Why?
| | HIV Reverse Transcriptase | 1 | 1993 | 29 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1083 | 0.030 |
Why?
| | CD8 Antigens | 1 | 1993 | 69 | 0.030 |
Why?
| | Blood Pressure | 1 | 2019 | 1538 | 0.030 |
Why?
| | CD3 Complex | 1 | 1993 | 92 | 0.030 |
Why?
| | Lymphocytes | 1 | 1994 | 330 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2013 | 155 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 718 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 536 | 0.030 |
Why?
| | Hospitalization | 1 | 2021 | 1749 | 0.030 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 182 | 0.030 |
Why?
| | Antigens, CD | 1 | 1994 | 442 | 0.020 |
Why?
| | P-Selectin | 1 | 2011 | 25 | 0.020 |
Why?
| | Blood Transfusion | 1 | 1994 | 293 | 0.020 |
Why?
| | E-Selectin | 1 | 2011 | 53 | 0.020 |
Why?
| | Tuberculosis, Pulmonary | 1 | 1993 | 112 | 0.020 |
Why?
| | Heteroduplex Analysis | 1 | 2011 | 1 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 105 | 0.020 |
Why?
| | Cell Proliferation | 2 | 2009 | 2186 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2017 | 479 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2011 | 121 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 157 | 0.020 |
Why?
| | Fibrinogen | 1 | 2011 | 154 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2011 | 224 | 0.020 |
Why?
| | Infant, Premature | 1 | 1994 | 476 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2011 | 168 | 0.020 |
Why?
| | Cross Infection | 1 | 1993 | 197 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2012 | 186 | 0.020 |
Why?
| | Nontuberculous Mycobacteria | 1 | 1993 | 204 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1342 | 0.020 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 6 | 0.020 |
Why?
| | L-Selectin | 1 | 2009 | 25 | 0.020 |
Why?
| | Human Experimentation | 1 | 2009 | 12 | 0.020 |
Why?
| | Tetanus | 1 | 2009 | 25 | 0.020 |
Why?
| | Candida | 1 | 2009 | 32 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2009 | 75 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2507 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1430 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 676 | 0.020 |
Why?
| | Meningitis, Aseptic | 1 | 2007 | 15 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2007 | 25 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1569 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 337 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 321 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 90 | 0.020 |
Why?
| | Paralysis | 1 | 2007 | 66 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2012 | 766 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2007 | 146 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1760 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 687 | 0.020 |
Why?
| | Kinetics | 1 | 2010 | 1551 | 0.020 |
Why?
| | Respiratory System | 1 | 2007 | 137 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1020 | 0.020 |
Why?
| | Immunoglobulin A, Secretory | 1 | 2005 | 9 | 0.020 |
Why?
| | Phosphates | 1 | 1987 | 159 | 0.020 |
Why?
| | Encephalitis | 1 | 2007 | 127 | 0.020 |
Why?
| | Muscles | 1 | 1987 | 320 | 0.020 |
Why?
| | Gastrointestinal Tract | 1 | 2007 | 169 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1314 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2005 | 108 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2279 | 0.010 |
Why?
| | Chemistry, Physical | 1 | 1984 | 37 | 0.010 |
Why?
| | Antigen-Antibody Reactions | 1 | 1984 | 50 | 0.010 |
Why?
| | Middle Aged | 2 | 2020 | 26719 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 723 | 0.010 |
Why?
| | Chemical Phenomena | 1 | 1984 | 80 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 1819 | 0.010 |
Why?
| | Myasthenia Gravis | 1 | 1984 | 18 | 0.010 |
Why?
| | Saliva | 1 | 2005 | 187 | 0.010 |
Why?
| | Body Mass Index | 1 | 2011 | 1956 | 0.010 |
Why?
| | Aging | 2 | 2003 | 1618 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1984 | 61 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1984 | 286 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1993 | 1477 | 0.010 |
Why?
| | Epithelium | 1 | 1984 | 295 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 371 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 742 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1143 | 0.010 |
Why?
| | Urban Population | 1 | 2003 | 397 | 0.010 |
Why?
| | Suspensions | 1 | 2000 | 30 | 0.010 |
Why?
| | Capsules | 1 | 2000 | 36 | 0.010 |
Why?
| | Drug Tolerance | 1 | 2000 | 79 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 144 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4509 | 0.010 |
Why?
| | Epithelial Cells | 1 | 1984 | 950 | 0.010 |
Why?
| | Administration, Oral | 1 | 2000 | 728 | 0.010 |
Why?
| | Macrophages | 1 | 1984 | 1261 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6112 | 0.010 |
Why?
| | Immunization | 1 | 2000 | 397 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1230 | 0.010 |
Why?
| | Mice | 1 | 1984 | 14860 | 0.000 |
Why?
| | Tail | 1 | 1987 | 29 | 0.000 |
Why?
| | Phosphocreatine | 1 | 1987 | 36 | 0.000 |
Why?
| | Animals | 2 | 1987 | 31694 | 0.000 |
Why?
| | Salamandridae | 1 | 1987 | 26 | 0.000 |
Why?
| | Aged | 1 | 1984 | 19061 | 0.000 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1987 | 473 | 0.000 |
Why?
| | Adenosine Triphosphate | 1 | 1987 | 430 | 0.000 |
Why?
|
|
McFarland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|